{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:43:02Z","timestamp":1789663382353,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.thromres.2022.08.002","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T22:24:56Z","timestamp":1660256696000},"page":"35-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Evaluation of different diagnostic tools for detection of acquired von Willebrand syndrome in patients with polycythemia vera or essential thrombocythemia"],"prefix":"10.1016","volume":"218","author":[{"given":"Snjezana","family":"Janjetovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Charlotte","family":"Rolling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Schneppenhem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Schafhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia Carlotta","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Holstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.thromres.2022.08.002_bb0005","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.thromres.2022.08.002_bb0010","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","article-title":"Myeloproliferative neoplasms in budd-chiari syndrome and portal vein thrombosis: a meta-analysis","volume":"120","author":"Smalberg","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.thromres.2022.08.002_bb0015","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.thromres.2022.08.002_bb0020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.patbio.2004.02.007","article-title":"A prospective analysis of thrombotic events in the european collaboration study on low-dose aspirin in polycythemia (ECLAP)","volume":"52","author":"Finazzi","year":"2004","journal-title":"Pathol. Biol."},{"issue":"22","key":"10.1016\/j.thromres.2022.08.002_bb0025","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.thromres.2022.08.002_bb0030","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Study Alliance leukemia (SAL). Bleeding, thrombosis and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the german SAL-MPN-registry","volume":"5","author":"Kaifie","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.thromres.2022.08.002_bb0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2016.11.011","article-title":"Factors related to the development of acquired von willebrand syndrome in patients with essential thrombocythemia and polycythemia vera","volume":"41","author":"Rottenstreich","year":"2017","journal-title":"Eur. J. Intern. Med."},{"issue":"12","key":"10.1016\/j.thromres.2022.08.002_bb0040","doi-asserted-by":"crossref","first-page":"914","DOI":"10.20452\/pamw.3211","article-title":"Prevalence of acquired von willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients","volume":"125","author":"Mital","year":"2015","journal-title":"Pol. Arch. Med. Wewn."},{"issue":"4","key":"10.1016\/j.thromres.2022.08.002_bb0045","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.thromres.2015.07.029","article-title":"Factors predisposing to acquired von willebrand syndrome during the course of polycythemia vera- retrospective analysis of 142 consecutive cases","volume":"136","author":"Mital","year":"2015","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.thromres.2022.08.002_bb0050","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.17219\/acem\/52361","article-title":"Acquired von Willebrand syndrome during the course of myelofibrosis: analysis of 32 cases","volume":"24","author":"Mital","year":"2015","journal-title":"Adv. Clin. Exp. Med."},{"issue":"5","key":"10.1016\/j.thromres.2022.08.002_bb0055","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood.V64.5.981.981","article-title":"Acquired von Willebrand's disease in the myeloproliferative syndrome","volume":"64","author":"Budde","year":"1984","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.thromres.2022.08.002_bb0060","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood.V82.6.1749.1749","article-title":"Elevated platelet count as a cause of abnormal von willebrand factor multimer distribution in plasma","volume":"82","author":"Budde","year":"1993","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2022.08.002_bb0065","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/10428199609074364","article-title":"Acquired von willebrand disease in myeloproliferative disorders","volume":"22","author":"van Genderen","year":"1996","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.thromres.2022.08.002_bb0070","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1055\/s-2007-996119","article-title":"Acquired von willebrand disease in patients with high platelet counts","volume":"23","author":"Budde","year":"1997","journal-title":"Semin. Thromb. Hemost."},{"issue":"12","key":"10.1016\/j.thromres.2022.08.002_bb0075","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/ajh.24592","article-title":"Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.thromres.2022.08.002_bb0080","first-page":"1226","article-title":"Qualitative and quantitative modifications of von willebrand factor in patients with essential thrombocythemia and controlled platelet count","volume":"13","author":"Lancellotti","year":"2015","journal-title":"JTH"},{"issue":"2","key":"10.1016\/j.thromres.2022.08.002_bb0085","first-page":"345","article-title":"Subcommittee on von willebrand factor. Acquired von willebrand syndrome: data from an international registry","volume":"84","author":"Federici","year":"2000","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2022.08.002_bb0090","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1538-7836.2008.02909.x","article-title":"Diagnostic workup of patients with acquired von willebrand syndrome: a retrospective single-Centre cohort study","volume":"6","author":"Tiede","year":"2008","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2022.08.002_bb0095","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1055\/s-2006-947866","article-title":"Laboratory testing for von willebrand disease: contribution of multimer analysis to diagnosis and classification","volume":"32","author":"Budde","year":"2006","journal-title":"Semin. Thromb. Hemost."},{"issue":"21","key":"10.1016\/j.thromres.2022.08.002_bb0100","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand's disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 5","key":"10.1016\/j.thromres.2022.08.002_bb0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2516.2008.01849.x","article-title":"Diagnosis of von willebrand disease subtypes: implications for treatment","volume":"14","author":"Budde","year":"2008","journal-title":"Haemophilia"},{"issue":"25","key":"10.1016\/j.thromres.2022.08.002_bb0110","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2022.08.002_bb0115","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2022.08.002_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.thromres.2022.08.002_bb0125","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.thromres.2022.08.002_bb0130","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/MBC.0000000000000169","article-title":"Performance evaluation and multicentre study of a von willebrand factor activity assay based on GPIb binding in the absence of ristocetin","volume":"25","author":"Patzke","year":"2014","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"1111","key":"10.1016\/j.thromres.2022.08.002_bb0135","article-title":"An international collaborative study to compare different von willebrand factor glycoprotein ib binding activity assays: the COMPASS-VWF study","volume":"10","author":"Szederjesi","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2022.08.002_bb0140","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/jth.14145","article-title":"A comparative analysis of different automated von willebrand factor glycoprotein ib-binding activity assays in well typed von willebrand disease patients","volume":"16","author":"Vangenechten","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2022.08.002_bb0145","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.thromres.2022.08.002_bb0150","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.thromres.2022.08.002_bb0155","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ajh.23417","article-title":"Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management","volume":"88","author":"Tefferi","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.thromres.2022.08.002_bb0160","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822003358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822003358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:49:14Z","timestamp":1758736154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384822003358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":32,"alternative-id":["S0049384822003358"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2022.08.002","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of different diagnostic tools for detection of acquired von Willebrand syndrome in patients with polycythemia vera or essential thrombocythemia","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2022.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}